Wedbush Reiterates Outperform Rating for Immunome (NASDAQ:IMNM)

Wedbush reissued their outperform rating on shares of Immunome (NASDAQ:IMNM) in a report issued on Monday,RTT News reports. The firm currently has a $33.00 price target on the stock.

Several other equities analysts also recently commented on the company. Stephens started coverage on Immunome in a research report on Friday, November 8th. They issued an “overweight” rating and a $30.00 price objective on the stock. Piper Sandler decreased their price objective on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $28.83.

Immunome Price Performance

Shares of NASDAQ:IMNM opened at $10.04 on Monday. The firm has a market capitalization of $626.67 million, a PE ratio of -1.24 and a beta of 1.90. The business has a 50 day simple moving average of $11.72 and a two-hundred day simple moving average of $12.98. Immunome has a 1 year low of $8.97 and a 1 year high of $30.96.

Insider Buying and Selling at Immunome

In other news, insider Robert Lechleider bought 15,805 shares of Immunome stock in a transaction on Thursday, November 21st. The stock was acquired at an average cost of $9.48 per share, for a total transaction of $149,831.40. Following the completion of the acquisition, the insider now owns 15,805 shares of the company’s stock, valued at $149,831.40. This trade represents a ∞ increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Clay B. Siegall purchased 66,057 shares of the firm’s stock in a transaction on Thursday, November 21st. The shares were purchased at an average cost of $9.54 per share, with a total value of $630,183.78. Following the completion of the transaction, the chief executive officer now owns 485,693 shares of the company’s stock, valued at approximately $4,633,511.22. The trade was a 15.74 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 102,862 shares of company stock valued at $978,045. Company insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Marshall Wace LLP increased its position in shares of Immunome by 228.5% during the second quarter. Marshall Wace LLP now owns 1,713,325 shares of the company’s stock worth $20,731,000 after purchasing an additional 1,191,774 shares in the last quarter. Janus Henderson Group PLC increased its position in Immunome by 10.3% during the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock valued at $50,971,000 after buying an additional 324,614 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in Immunome by 217.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 442,477 shares of the company’s stock valued at $6,469,000 after buying an additional 302,916 shares during the last quarter. Victory Capital Management Inc. boosted its holdings in Immunome by 48.1% in the third quarter. Victory Capital Management Inc. now owns 730,785 shares of the company’s stock worth $10,684,000 after acquiring an additional 237,497 shares in the last quarter. Finally, AXA S.A. purchased a new stake in shares of Immunome during the second quarter worth about $2,174,000. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.